QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of | (I.R.S. Employer Identification No.) | ||||
incorporation or organization) | |||||
(Address of principal executive offices) | (Zip Code) |
Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||||||
Preferred Stock Purchase Rights | ||||||||
Large accelerated filer | Accelerated filer | Smaller reporting company | Emerging growth company | |||||||||||||||||||||||
☐ | ☐ | ☐ |
Item 1. | ||||||||
Balance Sheets as of June 30, 2022 (unaudited) and December 31, 2021 | ||||||||
Statements of Operations (unaudited) for the Quarters and Six Months Ended June 30, 2022 and 2021 | ||||||||
Statements of Changes in Stockholders' Equity (unaudited) for the Quarters and Six Months Ended June 30, 2022 and 2021 | ||||||||
Statements of Cash Flows (unaudited) for the Six Months Ended June 30, 2022 and 2021 | 4 | |||||||
Item 2. | 10 | |||||||
Item 3. | 15 | |||||||
Item 4. | 15 | |||||||
Item 1. | 16 | |||||||
Item 1A. | 16 | |||||||
Item 2. | 16 | |||||||
Item 3. | 16 | |||||||
Item 4. | 16 | |||||||
Item 5. | 16 | |||||||
Item 6. | 16 | |||||||
17 |
June 30, 2022 | December 31, 2021 | ||||||||||
(Unaudited) | |||||||||||
Assets | |||||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | $ | |||||||||
Held-to-maturity securities | |||||||||||
Accounts receivable, net | |||||||||||
Inventories | |||||||||||
Prepaid expenses and other current assets | |||||||||||
Total current assets | |||||||||||
Fixed assets, net | |||||||||||
Right of use asset | |||||||||||
Other long-term assets | |||||||||||
Total assets | $ | $ | |||||||||
Liabilities and Stockholders’ Equity | |||||||||||
Current liabilities: | |||||||||||
Accounts payable | $ | $ | |||||||||
Accrued expenses and compensation | |||||||||||
Accrued product returns | |||||||||||
Lease obligation, current | |||||||||||
Total current liabilities | |||||||||||
Lease obligation, net of current portion | |||||||||||
Total liabilities | |||||||||||
Commitments and contingencies | |||||||||||
Stockholders’ equity: | |||||||||||
Preferred stock | |||||||||||
Convertible preferred stock | |||||||||||
Common stock, $ | |||||||||||
Additional paid-in capital | |||||||||||
Accumulated deficit | ( | ( | |||||||||
Total stockholders’ equity | |||||||||||
Total liabilities and stockholders’ equity | $ | $ |
Quarters Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||
Revenues | $ | $ | $ | $ | |||||||||||||||||||
Cost of revenues | |||||||||||||||||||||||
Gross profit | |||||||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||
Research and development | |||||||||||||||||||||||
Sales and marketing | |||||||||||||||||||||||
General and administrative | |||||||||||||||||||||||
Total operating expenses | |||||||||||||||||||||||
Loss from operations | ( | ( | ( | ( | |||||||||||||||||||
Other income | |||||||||||||||||||||||
Net loss | $ | ( | $ | ( | $ | ( | $ | ( | |||||||||||||||
Net loss per common share applicable to common stockholders, basic and diluted | $ | ( | $ | ( | $ | ( | $ | ( | |||||||||||||||
Series B Convertible Preferred Stock | Common Stock | Additional Paid-In Capital | Accumulated Deficit | Total | |||||||||||||||||||||||||||||||||||||
Number of Shares | Amount | Number of Shares | Amount | ||||||||||||||||||||||||||||||||||||||
Balance at December 31, 2020 | $ | $ | $ | $ | ( | $ | |||||||||||||||||||||||||||||||||||
Stock-based compensation expense | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
Issuance of common stock under at the market offering | — | — | — | ||||||||||||||||||||||||||||||||||||||
Net loss | — | — | — | — | — | ( | ( | ||||||||||||||||||||||||||||||||||
Balance at March 31, 2021 | ( | ||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
Issuance of common stock under at the market offering | — | — | — | ||||||||||||||||||||||||||||||||||||||
Issuance of common stock under employee stock purchase plan | — | — | — | ||||||||||||||||||||||||||||||||||||||
Vesting of restricted stock under equity plan | — | — | ( | — | — | ||||||||||||||||||||||||||||||||||||
Net loss | — | — | — | — | — | ( | ( | ||||||||||||||||||||||||||||||||||
Balance at June 30, 2021 | $ | $ | $ | $ | ( | $ | |||||||||||||||||||||||||||||||||||
Series B Convertible Preferred Stock | Common Stock | Additional Paid-In Capital | Accumulated Deficit | Total | |||||||||||||||||||||||||||||||||||||
Number of Shares | Amount | Number of Shares | Amount | ||||||||||||||||||||||||||||||||||||||
Balance at December 31, 2021 | $ | $ | $ | $ | ( | $ | |||||||||||||||||||||||||||||||||||
Stock-based compensation expense | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
Issuance of common stock under at the market offering | — | — | — | ||||||||||||||||||||||||||||||||||||||
Vesting of restricted stock under equity plan | — | — | ( | — | — | ||||||||||||||||||||||||||||||||||||
Net loss | — | — | — | — | — | ( | ( | ||||||||||||||||||||||||||||||||||
Balance at March 31, 2022 | ( | ||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
Issuance of common stock under employee stock purchase plan | — | — | — | — | |||||||||||||||||||||||||||||||||||||
Issuance of common stock to settle compensation obligation | — | — | — | ||||||||||||||||||||||||||||||||||||||
Vesting of restricted stock under equity plan | — | — | ( | — | — | ||||||||||||||||||||||||||||||||||||
Net loss | — | — | — | — | — | ( | ( | ||||||||||||||||||||||||||||||||||
Balance at June 30, 2022 | $ | $ | $ | $ | ( | $ |
Six Months Ended June 30, | |||||||||||
2022 | 2021 | ||||||||||
Cash flows from operating activities: | |||||||||||
Net loss | $ | ( | $ | ( | |||||||
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||||
Depreciation | |||||||||||
Stock-based compensation | |||||||||||
Issuance of common stock to settle compensation obligations | |||||||||||
Impairment charge against right of use asset | |||||||||||
Loss on disposal of fixed assets | |||||||||||
Accretion of interest income on held-to-maturity securities | ( | ||||||||||
Changes in operating assets and liabilities: | |||||||||||
Accounts receivable | ( | ( | |||||||||
Inventories | ( | ||||||||||
Prepaid expenses and other current and long-term assets | |||||||||||
Accounts payable | |||||||||||
Accrued expenses and compensation | ( | ||||||||||
Accrued product returns | ( | ( | |||||||||
Net cash used in operating activities | ( | ( | |||||||||
Cash flows from investing activities: | |||||||||||
Purchases of held-to-maturity securities | ( | ||||||||||
Purchases of fixed assets | ( | ( | |||||||||
Net cash used in investing activities | ( | ( | |||||||||
Cash flows from financing activities: | |||||||||||
Net proceeds from issuance of stock | |||||||||||
Net cash provided by financing activities | |||||||||||
Net (decrease) increase in cash and cash equivalents | ( | ||||||||||
Cash and cash equivalents, beginning of period | |||||||||||
Cash and cash equivalents, end of period | $ | $ | |||||||||
Supplemental disclosure of cash flow information: | |||||||||||
Issuance of common stock to settle compensation obligation | $ | $ |
Quarters Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||
Net loss applicable to common stockholders | $ | ( | $ | ( | $ | ( | $ | ( | |||||||||||||||
Weighted average number of common shares outstanding, basic and dilutive | |||||||||||||||||||||||
Net loss per common share applicable to common stockholders, basic and diluted | $ | ( | $ | ( | $ | ( | $ | ( | |||||||||||||||
June 30, | |||||||||||
2022 | 2021 | ||||||||||
Options | |||||||||||
Unvested restricted stock awards | |||||||||||
Unvested restricted stock units | |||||||||||
Convertible preferred stock | |||||||||||
Total |
June 30, 2022 | December 31, 2021 | ||||||||||
Purchased components | $ | $ | |||||||||
Finished goods | |||||||||||
$ | $ |
June 30, 2022 | December 31, 2021 | ||||||||||
Professional services | $ | $ | |||||||||
Compensation | |||||||||||
Warranty | |||||||||||
Leasehold | |||||||||||
Sales tax | |||||||||||
Other | |||||||||||
$ | $ |
2022 | $ | |||||||
2023 | ||||||||
2024 | ||||||||
2025 | ||||||||
Total minimum lease payments | $ | |||||||
Discount rate, | $ | |||||||
Lease obligation, current portion | ||||||||
Lease obligation, net of current portion | ||||||||
$ |
Fair Value Measurements at June 30, 2022 Using | |||||||||||||||||||||||
June 30, 2022 | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | ||||||||||||||||||||
Assets: | |||||||||||||||||||||||
Cash equivalents | $ | $ | $ | $ | |||||||||||||||||||
Total | $ | $ | $ | $ |
Fair Value Measurements at December 31, 2021 Using | |||||||||||||||||||||||
December 31, 2021 | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | ||||||||||||||||||||
Assets: | |||||||||||||||||||||||
Cash equivalents | $ | $ | $ | $ | |||||||||||||||||||
Total | $ | $ | $ | $ | |||||||||||||||||||
June 30, 2022 | December 31, 2021 | ||||||||||
Preferred stock, $ | $ | $ | |||||||||
Series B convertible preferred stock, $ | $ | $ | |||||||||
Quarter ended June 30, | Increase (Decrease) | ||||||||||||||||||||||
2022 | 2021 | Amount | Percent | ||||||||||||||||||||
Revenues | $ | 2,138,301 | $ | 2,213,499 | $ | (75,198) | (3.4) | % | |||||||||||||||
Gross profit | $ | 1,452,180 | $ | 1,655,278 | $ | (203,098) | (12.3) | % | |||||||||||||||
–% of revenues | 67.9 | % | 74.8 | % | (6.9) | % | |||||||||||||||||
Operating expenses | $ | 2,662,498 | $ | 2,187,241 | $ | 475,257 | 21.7 | % | |||||||||||||||
Other income, net | $ | 50,395 | $ | 379 | $ | 50,016 | 13,196.8 | % | |||||||||||||||
Net loss | $ | (1,159,923) | $ | (531,584) | $ | 628,339 | 118.2 | % | |||||||||||||||
Net loss per common share | $ | (0.17) | $ | (0.13) | $ | 0.04 | 30.8 | % |
Six months ended June 30, | Increase (Decrease) | ||||||||||||||||||||||
2022 | 2021 | Amount | Percent | ||||||||||||||||||||
Revenues | $ | 4,440,692 | $ | 4,368,971 | $ | 71,721 | 1.6 | % | |||||||||||||||
Gross profit | $ | 3,245,697 | $ | 3,234,461 | $ | 11,236 | 0.3 | % | |||||||||||||||
–% of revenues | 73.1 | % | 74.0 | % | (0.9) | % | |||||||||||||||||
Operating expenses | $ | 5,418,005 | $ | 3,826,619 | $ | 1,591,386 | 41.6 | % | |||||||||||||||
Other income, net | $ | 53,823 | $ | 791 | $ | 53,032 | 6,704.4 | % | |||||||||||||||
Net loss | $ | (2,118,485) | $ | (591,367) | $ | 1,527,118 | 258.2 | % | |||||||||||||||
Net loss per common share | $ | (0.30) | $ | (0.15) | $ | 0.15 | 100.0 | % |
June 30, | December 31, | ||||||||||||||||
2022 | 2021 | 2021 | |||||||||||||||
Cash, cash equivalents and securities | $ | 22,968,146 | $ | 8,364,197 | $ | 22,572,104 | |||||||||||
Working capital | $ | 23,039,380 | $ | 8,448,353 | $ | 22,822,162 | |||||||||||
Current ratio | 15.5 | 6.3 | 17.7 | ||||||||||||||
Days sales outstanding | 25.9 | 19.0 | 14.1 | ||||||||||||||
Inventory turnover | 3.5 | 2.2 | 2.2 |
Six months ended June 30, | |||||||||||||||||
2022 | 2021 | Change | |||||||||||||||
Net cash provided by (used in): | |||||||||||||||||
Operating activities | $ | (1,578,682) | $ | (568,738) | $ | (1,009,944) | |||||||||||
Investing activities | (16,941,974) | (83,273) | (16,858,701) | ||||||||||||||
Financing activities | 1,950,881 | 3,789,995 | (1,839,114) | ||||||||||||||
Net change in cash and cash equivalents | $ | (16,569,775) | $ | 3,137,984 |
Exhibit No. | Description | |||||||
Certification of Principal Executive Officer Under Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, and pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002. Filed herewith. | ||||||||
Certification of Principal Financial Officer Required Under Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended, and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Filed herewith. | ||||||||
Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350. Furnished herewith. | ||||||||
101.INS | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). Filed herewith. | |||||||
101.SCH | Inline XBRL Taxonomy Extension Schema Document. Filed herewith. | |||||||
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. Filed herewith. | |||||||
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. Filed herewith. | |||||||
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. Filed herewith. | |||||||
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. Filed herewith. | |||||||
104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). Filed herewith. | |||||||
NEUROMETRIX, INC. | ||||||||
July 21, 2022 | /s/ | SHAI N. GOZANI, M.D., PH. D. | ||||||
Shai N. Gozani, M.D., Ph. D. | ||||||||
Chairman, President and Chief Executive Officer | ||||||||
July 21, 2022 | /s/ | THOMAS T. HIGGINS | ||||||
Thomas T. Higgins | ||||||||
Senior Vice President, Chief Financial Officer and Treasurer |
1. | I have reviewed this Quarterly Report on Form 10-Q of NeuroMetrix, Inc.; | |||||||
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | |||||||
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | |||||||
4. | The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: | |||||||
a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |||||||
b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |||||||
c) | evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |||||||
d) | disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and | |||||||
5. | The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): | |||||||
a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and | |||||||
b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
Date: | July 21, 2022 | /s/ SHAI N. GOZANI, M.D., PH. D. | ||||||
Shai N. Gozani, M.D., Ph.D. | ||||||||
Chairman, President and Chief Executive Officer |
I, Thomas T. Higgins, certify that: | ||||||||
1. | I have reviewed this Quarterly Report on Form 10-Q of NeuroMetrix, Inc.; | |||||||
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | |||||||
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | |||||||
4. | The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: | |||||||
a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |||||||
b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |||||||
c) | evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |||||||
d) | disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and | |||||||
5. | The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): | |||||||
a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and | |||||||
b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
Date: | July 21, 2022 | /s/ THOMAS T. HIGGINS | ||||||
Thomas T. Higgins | ||||||||
Senior Vice President, Chief Financial Officer and Treasurer |
/s/ SHAI N. GOZANI, M.D., PH. D. | |||||
Shai N. Gozani, M.D., Ph.D. | |||||
Chairman, President and Chief Executive Officer | |||||
/s/ THOMAS T. HIGGINS | |||||
Thomas T. Higgins | |||||
Senior Vice President, Chief Financial Officer and Treasurer |
Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2022 |
Jun. 30, 2021 |
Jun. 30, 2022 |
Jun. 30, 2021 |
|
Revenue from Contract with Customer, Including Assessed Tax | $ 2,138,301 | $ 2,213,499 | $ 4,440,692 | $ 4,368,971 |
Other Nonoperating Income | 50,395 | 379 | 53,823 | 791 |
Net loss | $ (1,159,923) | $ (531,584) | $ (2,118,485) | $ (591,367) |
Earnings Per Share, Diluted | $ (0.17) | $ (0.13) | $ (0.30) | $ (0.15) |
Earnings Per Share, Basic | $ (0.17) | $ (0.13) | $ (0.30) | $ (0.15) |
Loss from operations | $ (1,210,318) | $ (531,963) | $ (2,172,308) | $ (592,158) |
Operating expenses: | ||||
Research and development | 915,799 | 641,525 | 1,626,376 | 874,802 |
Sales and marketing | 566,598 | 269,493 | 1,425,437 | 663,318 |
General and administrative | 1,180,101 | 1,276,223 | 2,366,192 | 2,288,499 |
Total operating expenses | 2,662,498 | 2,187,241 | 5,418,005 | 3,826,619 |
Gross profit | 1,452,180 | 1,655,278 | 3,245,697 | 3,234,461 |
Cost of revenues | $ 686,121 | $ 558,221 | $ 1,194,995 | $ 1,134,510 |
Business and Basis of Presentation |
6 Months Ended |
---|---|
Jun. 30, 2022 | |
Accounting Policies [Abstract] | |
Business and Basis of Presentation | Business and Basis of Presentation Our Business-An Overview NeuroMetrix, Inc. (the "Company" or "NeuroMetrix") develops and commercializes health care products that utilize non-invasive neurostimulation. Revenues are derived from the sale of medical devices and after-market consumable products and accessories. The Company’s products are sold in the United States and select overseas markets. They are cleared by the U.S. Food and Drug Administration ("FDA") and regulators in foreign jurisdictions where appropriate. The Company has two primary products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. Quell® is a wearable neuromodulation technology indicated for treatment of fibromyalgia symptoms and chronic lower extremity pain. The Company held cash, cash equivalents and held-to-maturity securities totaling $23.0 million as of June 30, 2022. The Company has a history of operating losses and has financed its operations primarily from sales of equity, sales of its products and third party development collaboration payments. The Company believes that its present balance of cash and securities resources coupled with cash inflows from product sales will enable the Company to fund its operations for at least the next twelve months from the date of issuance of the financial statements. Actual cash requirements could differ from management's projections for many reasons. These include the effects of the Covid-19 pandemic on sales, procurement of production materials, and maintenance of critical staffing. They could also include changes the Company may make to its business strategy that affect operating expenses, regulatory developments, changes to research and development spending plans; and other items affecting the Company's projected uses of cash. Unaudited Interim Financial Statements The accompanying unaudited balance sheet as of June 30, 2022, unaudited statements of operations, changes in stockholders' equity for the quarters and six months ended June 30, 2022 and 2021 and cash flows for the six months ended June 30, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying balance sheet as of December 31, 2021 does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, the financial statements include all normal and recurring adjustments considered necessary for a fair presentation of the Company’s financial position and operating results. Operating results for the six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, or the SEC, on January 28, 2022 (File No. 001-33351). Revenues Revenues include product sales, net of estimated returns. Revenue is measured as the amount of consideration the Company expects to receive in exchange for product transferred. Revenue is recognized when contractual performance obligations have been satisfied and control of the product has been transferred to the customer. In most cases, the Company has a single product delivery performance obligation. Accrued product returns are estimated based on historical data and evaluation of current information. Accounts receivable are recorded at the amount the Company expects to collect, net of the allowance for doubtful accounts receivable. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses based on customer past payment history, product usage activity, and recent communications with the customer. Individual customer balances which are over 90 days past due are reviewed individually for collectability and written-off when recovery is not probable. Allowance for doubtful accounts was $25,000 as of June 30, 2022 and December 31, 2021. One customer accounted for 34% and 39% of total revenues in the quarter and six months ended June 30, 2022, respectively. One customer accounted for 26% and 31% of total revenues in the quarter and six months ended June 30, 2021, respectively. One customer accounted for 40% and two customers accounted for 35% of accounts receivable as of June 30, 2022 and December 31, 2021, respectively. Held-To-Maturity Securities The Company's investments in held-to-maturity securities consist of investment grade U.S. Treasury obligations, commercial paper and corporate bonds with maturity dates of less than 365 days. The Company has the ability and intention to hold these securities until maturity. Accordingly, these securities are recorded in the Company's balance sheet at amortized cost and interest is recorded within other income on the Company's statement of operations. The market value of the held-to-maturity securities at June 30, 2022 was $16,796,840. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.
|
Comprehensive Loss |
6 Months Ended |
---|---|
Jun. 30, 2022 | |
Equity [Abstract] | |
Comprehensive Loss | Comprehensive Loss For the quarters and six months ended June 30, 2022 and 2021, the Company had no components of other comprehensive loss other than net loss itself.
|
Net Loss Per Common Share |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Loss Per Common Share | Net Loss Per Common Share Basic and dilutive net loss per common share were as follows:
Shares underlying the following potentially dilutive weighted average number of common stock equivalents were excluded from the calculation of diluted net loss per common share because their effect was anti-dilutive for each of the periods presented:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] |
|
Inventories |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories | Inventories Inventories consist of the following:
|
Accrued Expenses |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payables and Accruals [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued Expenses | Accrued Expenses and Compensation Accrued expenses and compensation consist of the following:
|
Leases Leases (Notes) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lessee, Operating Leases [Text Block] | Operating Leases The Company's lease on its Woburn, Massachusetts corporate office and manufacturing facility extends through September 2025 with a monthly base rent of $13,846 and a 5-year extension option. Future minimum lease payments under this non-cancellable operating lease as of June 30, 2022 are as follows:
The Company's lease on its former corporate office in Waltham, Massachusetts expired in February 2022. During the first quarter of 2021, the Company recorded an impairment charge of $126,748 on that idle facility which was being offered for sublet. In the first quarter of 2022, a $60,000 reduction in rent expense was recorded upon return of the facility to the lessor. The letter of credit issued by a bank in favor of the Waltham facility was released. For the six months ended June 30, 2022, the Company recorded sublet income totaling $22,795 within operating expenses on the Company's statement of operations. Total recorded rent expense was $46,102 and $57,453, for the quarters ended June 30, 2022 and 2021, respectively. Total recorded rent expense was $70,856 and $224,357 for the six months ended June 30, 2022 and 2021, respectively. The Company records rent expense on its facility lease on a straight-line basis over the lease term. The remaining operating lease term was 3.2 years as of June 30, 2022.
|
Fair Value Measurements |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements | Fair Value Measurements Assets and liabilities that are measured at fair value are presented below. All Company assets and liabilities measured at fair value utilize Level 1 inputs (i.e. quoted prices (unadjusted) in active markets for identical assets or liabilities).
|
Stockholders' Equity |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity | Stockholders’ Equity Preferred stock and convertible preferred stock consist of the following:
2022 equity activity In January 2022, the Company issued 292,500 shares of common stock under an at-the-market (ATM) equity offering program with net proceeds of $1,943,052 and issued 20,000 restricted stock awards under its 2004 Stock Option Plan with a value of $104,200. In April 2022, the Company issued 76,000 shares of restricted common stock under its 2022 Equity Incentive Plan with a value of $326,000 to employees as long term incentives (LTI) and issued 50,213 shares of fully vested common stock with a value of $215,417 in settlement of management incentive compensation. In May 2022, the Company issued 161,764 restricted stock units with a value of $550,000 as LTI to its management and directors under its 2022 Equity Incentive Plan. In June 2022, the Company issued 2,503 shares of fully vested common stock with a value of $7,829 pursuant to the Company's Employee Stock Purchase Plan. As of June 30, 2022, the Company had issued 119,333 shares of restricted common stock and 161,764 restricted stock units that remain unvested. At December 31, 2021 the Company had issued 30,000 shares of restricted common stock that were unvested. Total compensation cost related to non-vested awards not yet recognized at June 30, 2022 was $1,183,449. These unrecognized costs are expected to be recognized over a weighted-average period of 2.5 years. 2021 equity activity In January 2021, the Company issued 2,408 shares of fully vested common stock with a value of $4,197 pursuant to the Company's Employee Stock Purchase Plan. In May 2021, the Company issued 42,808 shares of restricted common stock with a value of $125,000 under its 2004 Stock Option Plan. As of June 30, 2021, 13,911 of these shares were vested, 7,493 shares were forfeited to settle withholding taxes on the vesting and 21,404 remain restricted. In June 2021, the Company issued 7,055 shares of fully vested common stock with a value of $18,950 pursuant to the Company's Employee Stock Purchase Plan. During the six months ended June 30, 2021, the Company issued 1,207,681 shares of its common stock, under the ATM for net proceeds of $3,766,848.
|
Business and Basis of Presentation (Policies) |
6 Months Ended |
---|---|
Jun. 30, 2022 | |
Accounting Policies [Abstract] | |
Unaudited Interim Financial Statements | Unaudited Interim Financial Statements The accompanying unaudited balance sheet as of June 30, 2022, unaudited statements of operations, changes in stockholders' equity for the quarters and six months ended June 30, 2022 and 2021 and cash flows for the six months ended June 30, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying balance sheet as of December 31, 2021 does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, the financial statements include all normal and recurring adjustments considered necessary for a fair presentation of the Company’s financial position and operating results. Operating results for the six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, or the SEC, on January 28, 2022 (File No. 001-33351).
|
Revenues | Revenues Revenues include product sales, net of estimated returns. Revenue is measured as the amount of consideration the Company expects to receive in exchange for product transferred. Revenue is recognized when contractual performance obligations have been satisfied and control of the product has been transferred to the customer. In most cases, the Company has a single product delivery performance obligation. Accrued product returns are estimated based on historical data and evaluation of current information. Accounts receivable are recorded at the amount the Company expects to collect, net of the allowance for doubtful accounts receivable. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses based on customer past payment history, product usage activity, and recent communications with the customer. Individual customer balances which are over 90 days past due are reviewed individually for collectability and written-off when recovery is not probable. Allowance for doubtful accounts was $25,000 as of June 30, 2022 and December 31, 2021. One customer accounted for 34% and 39% of total revenues in the quarter and six months ended June 30, 2022, respectively. One customer accounted for 26% and 31% of total revenues in the quarter and six months ended June 30, 2021, respectively. One customer accounted for 40% and two customers accounted for 35% of accounts receivable as of June 30, 2022 and December 31, 2021, respectively.
|
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.
|
Marketable Securities, Policy | Held-To-Maturity Securities The Company's investments in held-to-maturity securities consist of investment grade U.S. Treasury obligations, commercial paper and corporate bonds with maturity dates of less than 365 days. The Company has the ability and intention to hold these securities until maturity. Accordingly, these securities are recorded in the Company's balance sheet at amortized cost and interest is recorded within other income on the Company's statement of operations. The market value of the held-to-maturity securities at June 30, 2022 was $16,796,840.
|
Net Loss Per Common Share (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share |
|
Inventories (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Inventory | Inventories consist of the following:
|
Accrued Expenses (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payables and Accruals [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Accrued Expenses | Accrued expenses and compensation consist of the following:
|
Leases Leases (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lessee, Operating Lease, Liability, Maturity [Table Text Block] |
|
Fair Value Measurements (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assets and Liabilities Measured at Fair Value on Recurring Basis |
|
Statement of Shareholders' Equity (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Stock by Class [Table Text Block] | Preferred stock and convertible preferred stock consist of the following:
|
Comprehensive Loss (Detail) - USD ($) |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2022 |
Jun. 30, 2021 |
Jun. 30, 2022 |
Jun. 30, 2021 |
|
Equity [Abstract] | ||||
Other Comprehensive Income (Loss), Net of Tax | $ 0 | $ 0 | $ 0 | $ 0 |
Net Loss Per Common Share Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) |
3 Months Ended | 6 Months Ended | ||||
---|---|---|---|---|---|---|
Jun. 30, 2022 |
Mar. 31, 2022 |
Jun. 30, 2021 |
Mar. 31, 2021 |
Jun. 30, 2022 |
Jun. 30, 2021 |
|
Earnings Per Share [Abstract] | ||||||
Net Income (Loss) Attributable to Parent | $ (1,159,923) | $ (958,562) | $ (531,584) | $ (59,783) | $ (2,118,485) | $ (591,367) |
Weighted Average Number of Shares Outstanding, Basic | 7,009,775 | 4,169,764 | 6,951,792 | 3,990,844 | ||
Weighted Average Number of Shares Outstanding, Diluted | 7,009,775 | 4,169,764 | 6,951,792 | 3,990,844 | ||
Earnings Per Share, Diluted | $ (0.17) | $ (0.13) | $ (0.30) | $ (0.15) | ||
Earnings Per Share, Basic | $ (0.17) | $ (0.13) | $ (0.30) | $ (0.15) |
Inventories (Detail) - USD ($) |
Jun. 30, 2022 |
Dec. 31, 2021 |
---|---|---|
Inventory [Line Items] | ||
Purchased components | $ 453,610 | $ 422,093 |
Finished goods | 415,768 | 284,460 |
Inventories | $ 869,378 | $ 706,553 |
Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) |
Jun. 30, 2022 |
Dec. 31, 2021 |
---|---|---|
Payables and Accruals [Abstract] | ||
Sales return allowance | $ 8,000 | $ 39,000 |
Accrued Leaseholds Current | 0 | 60,000 |
Professional services | 224,000 | 109,000 |
Accrued Salaries, Current | 543,075 | 440,474 |
Warranty reserve | 21,700 | 28,400 |
Other | 114,004 | 67,493 |
Sales and Excise Tax Payable, Current | 127,828 | 108,788 |
Accrued expenses | $ 1,030,607 | $ 814,155 |
Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($) |
Jun. 30, 2022 |
Dec. 31, 2021 |
---|---|---|
Assets | ||
Cash equivalents | $ 5,030,666 | $ 20,317,736 |
Assets, Fair Value Disclosure | 5,030,666 | 20,317,736 |
Level 1 | ||
Assets | ||
Cash equivalents | 5,030,666 | 20,317,736 |
Assets, Fair Value Disclosure | 5,030,666 | 20,317,736 |
Level 2 | ||
Assets | ||
Cash equivalents | 0 | 0 |
Assets, Fair Value Disclosure | 0 | 0 |
Level 3 | ||
Assets | ||
Cash equivalents | 0 | 0 |
Assets, Fair Value Disclosure | $ 0 | $ 0 |
Preferred Stock and Convertible Preferred Stock (Details) - USD ($) |
Jun. 30, 2022 |
Dec. 31, 2021 |
---|---|---|
Preferred Non-Convertible Stock | ||
Class of Stock [Line Items] | ||
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Value of preferred stock issued | $ 0 | $ 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Series B Convertible Preferred Stock | ||
Class of Stock [Line Items] | ||
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 147,000 | 147,000 |
Preferred stock, shares issued (in shares) | 200 | 200 |
Value of preferred stock issued | $ 1 | $ 1 |
Preferred stock, shares outstanding (in shares) | 200 | 200 |
Label | Element | Value |
---|---|---|
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | $ 22,572,104 |
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | $ 5,226,213 |
)JW:Y+NYYK@T0#6T*>5I"G:+&J;KQ->0T/K4,>UVH:
MF&A42[ZSBN_LF_CNN Q%T$R(JWVP\J$Q+?D&%=\ +=$$X((",&(K&Q$>OV21
MLO7F*1K6$FI800WWRBXBCB&ISK7POQR1>3X1D?>95IHE09A8:5'A;\VPA=A)
M+F8,T>/XS/6<_N!LU'NTX+E./>LZ^P!>Q5RN (2\!06]-L I2ZQ)=(=@8S/B
M<2W;T=VR%^X^H/,U,#Y=IQD/CVN+1&H_NEUT>GE/KG+ CWG6Z'ZQ8:%A;
MK-K:N*AWJ,9?.0'>\U1(;?KI7#-MSYL[%#];+>04CVK+69L8=R\7,X\9],Z+
M3,'/RDZ'ZVB9V7OG(>R+6_L7%[< H/YT1MF<$
MM\;U?AG[5BE+7*>:9\2=2[CF"\GG/&/2PE=;H'X1J34/X)29 O"AXH],^&;O
MX+ 3$6J2)*_L_;WCN!N?K%DWRC+QIHH=$L\PPW)&-'M=+ZG;R/P[_O^DQE&G
MUSWJ'/62U\YVL6^IV70YP[5A4J)>^)%I(%.5M/5<::/M5![7P^A/>CW2+YE>
M<&E X)Q*HX,C&H*Z'I.U8]72CZ:9LC3HO%G0GP6U2Z#UN:*=;!S7H/U7I;\!
M4$L#!!0 ( J']52V/7R]R ( ,,& 9 >&PO=V]R:W-H965T /.I@%6VT)I_IM S+[*X)3^
MDV4 4FW W)C: 2F.ZI.QU""A[R2"0S@Z.$OB9+#5FJ+F1#S>MT*[?,6]TVU7
M.1J^D'03W^\J>4'_KZWFV75 BF,P>IODVX\&Z*HJC*=.T^30.PF1R=5'-N\FN+M*=B,*$WV0DW\5QD#V_
MY5'Z=#FADY<9M^'#1I0SIE<7V^"!?^#BT_8F*Z:F>\HZC'F2AVE",GY_.7E#
MSWUFE@75$G^$_"D_^$[*5;E+TS_+"7]].='*%O&(KT2)"(J/1W[-HZ@D%>WX
MJX%.]IIEX>'W%[I3K7RQ,G=!SJ_3Z'.X%IO+B3DA:WX?[")QFSYYO%DAH^2M
MTBBO_B=/];+& Y=",R
M*5_$F6B]^;7U)X^V K#<3T<=X=/(*9]8&0?&*G]T0%_LXV4O-2(*06!7=CBV3GP
M[0ZJ_7.AUBSE5R/8((K++1]-W_R"0^^M+;H3.>O$2O>Q4I?WZ8RI%6+E J75
M!?^YR;8LA^"5+>J=J[!V56WR[33T/$))
M63OE'>"#:5)*@?6M+\@?'5,&U) %!.\0W!VN^?V3_'A\8V_7/L(#Z>/>(6M;
MP7.V$4",'%T;F=]64A36SP_DQY"&Z8S.HOC,KM(XI.DT<7)$PW!*DVG:OYF%
M-,XF9^2+*U8DP>Y 8>\A35=O,#19/HE.$VQCVN!18-I06_W_/)@)#8(9G4Q2
MDM P0RE+2$9G:4@GLXC$=#8+Z#1)'N-Y=H#?#?"97Z2-L03GX>1L$.)!B(/]
M#L:[[B/H\+"5>, B*E@N">[:J6!QG FQ,-C/+OO'XRE1N!;Q^^80 #=IP#<
MYZ*SUUHJ63M/.1-Y)YCKO6B^I_YR*FT@9YT&:\P5@;+$QDUVF%L,:?XT4L0/
M$0&65Q;4^D$<+@O$LZG=H(N+8ZGU>VN):))&,4V#E*1I0H,D)9^;.]"6%UH;
MQ7,K]B&R'5,(&X8S&L
&Z*
M>6_:@QQ7K"G-%[GY%5M_4HN7R5*[7]AXV82$LT8;6;7*Q*#BPO^SUS8.>PK3
M\(A"W"K$CK
MQ2[<5\H5*35/"6&ODBS[29V"V5N*:_J<>D3?N8)T;P'/B!9/F7AB0;X5$F^[
ML&DWB!6=0VS/(=P8+N
[5
M?95]K";Y$P
MLS6:N;#>V&BMAC*SC$LE]%.JXU3\J]XI7[B4Z $$6O"BT-8N,R( _8B6>L^D
M50Z(K] =4S2E>65,1TM(*D$5!8D^OB9YE4**5H(7!J"L%+$+I(,^$L$H6]?@
M->J[#Z (S=]K>&D&Y,Q56H8AXR8-Y?N:LG^&6%;_]44#H\\*"OEW
MG\LUBTD_"W-\W,J2)#!W]/D@06S B;__#D?>3WT6C036,6S2&C890H]_YXKD
MB!S:)O>V0<
;'_B2D%2T3 %.3J9;(:A;]TJ)O
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M.DTAN4Z[.6Y\4[W>/6Y\4'W^'''^--R[S\< N7^$'Q0.D'G-GDCJ8/7DC)0E);U
MN>P>[L??)55^